The U.S. Food and Drug Administration (FDA) has approved Zepbound (tirzepatide), marking the first medication authorized for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The approval comes with specific guidelines requiring the drug to be used alongside a reduced-calorie diet and increased physical activity. Dr. Sally Seymour, director of the FDA’s Division of Pulmonology, Allergy, and Critical Care, stated, “Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea. This is a major step forward for patients with obstructive sleep apnea.” Clinical Evidence and Effectiveness The FDA based its approval … Continue reading FDA Approves Zepbound: First Sleep Apnea Drug Reduces Breathing Events by 25/hour, 18% Weight Loss